n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA), from fish oil (FO), in rodents have been shown to reduce adipogenesis. Evidence of an effect on adipose tissue mass in humans is limited, and no studies have specifically aimed to elucidate this in infancy. To explore whether n-3 LCPUFA intake affects adipose tissue growth, we randomly allocated 154 healthy infants to daily supplementation with FO or sunflower oil (SO) from 9 to 18 mo of age and measured z-score changes in various anthropometric assessments of body size and skinfold thicknesses and plasma adipokine concentrations. Among the 133 completing infants, erythrocyte n-3 PUFA increased more in those receiving FO than in infants receiving SO [12.2 Ϯ 0.7 (mean Ϯ SE) versus 2.0 Ϯ 0.4 fatty acid percentage (FA%), p Ͻ 0.001] with a concomitant larger decrease in n-6 PUFA (Ϫ8.9 Ϯ 0.7 versus Ϫ0.9 Ϯ 0.6 FA%, p Ͻ 0.001). We found no association between FO consumption relative to SO consumption and any of the anthropometric measures related to the size of the fat mass, but infants in the FO group had a lower skinfold ratio (triceps/ subscapular) at 18 mo than those in SO group (p ϭ 0.02). Our findings do not support the hypothesis that dietary n-3 LCPUFA is important for infant fat mass, but future studies testing this specifically are warranted. A sedentary lifestyle that favors a positive energy balance is generally acknowledged as the major cause of the increasing prevalence of obesity, but other potential contributing factors are also receiving attention. Among these are the dietary changes in the consumption of polyunsaturated fatty acids (PUFA) toward a higher n-6 and lower n-3 PUFA intake, which has been suggested as a partial explanatory factor (1). Dietary n-3 long-chain PUFA (LCPUFA) in rodents has been shown to prevent diet-induced obesity (2) and has also been reported to enhance fat mass reduction in two randomized weight-loss trials in overweight adults (3) and obese women with type-2 diabetes (4).Early life is a period of rapid growth with major changes in both body size and composition. It is well established that docosahexaenoic acid (DHA, 22:6n-3) is important for, e.g., visual development in infancy (5), but it is presently unknown to what extent n-3 LCPUFA should be considered relevant with respect to adiposity. The natural content of n-3 PUFA in breast milk has been found to be positively associated with infant weight gain in preterm (6) but not term-born infants (7). Furthermore, two intervention studies giving n-3 LCPUFA to pregnant and/or lactating mothers suggest a programming effect on later infant BMI, although in opposite directions (8,9). However, no studies have to our knowledge aimed specifically to investigate whether dietary n-3 LCPUFA in early life is associated with the size of the fat mass per se.Inspired by the clear finding in rodents, this study was conducted to attempt to elucidate whether growth and fat deposition in healthy Danish infants during the complementary feeding period, 9 -18 mo of age, are associ...